Explore
Companies
Investors
Top 50
Streams
Trending tech news
Latest investments
Latest acquisitions
Products
Automate
Trackers
Innovation Services
About Index
Index
By TNW
Log in
Register
Jounce Therapeutics
3128
Jounce Therapeutics
Technology
Biotechnology
Jounce Therapeutics is developing cancer immune-therapies to harness the immunesystem to attack cancerous cells and tumors.
Suggest edits
Founded
2013
Raised
$158M
Follow us
Also headquartered in Cambridge
MIT
Raspberry Pi
ARM
Xconomy
Money Mover
Biogen
HubSpot
Formlabs
General Catalyst
Akamai
Companies in the same industry
Novadip Biosciences
CellFE, Inc
Suzhou Ribo Life Science
Meridian Bioscience, Inc.
Novavax AB
BioVL
Protera
AsclepiX Therapeutics
polymaterialtd
Lepu Bio
Alexa global traffic share
Overview
Funding
2
Add info
Latest funding
$102,000,000
IPO - 2017
$56,000,000
Venture capital (Series B) - 2015
Redmile Group
Foresite Capital
Wellington Management
+5
Team Size
50+
Employees
I work here
Location
Cambridge
,
United States
Headquarters
Explore Cambridge
$102,000,000
IPO
Xconomy
Jounce Gets $102M As Biotech IPOs Gain Steam in ’17
Stock markets
Earnings
$56,000,000
Venture capital (Series B)
VentureWire
The Daily Startup: Jounce Therapeutics Raises $56M as Immunotherapy Stays Hot
Funding
